| Literature DB >> 29181405 |
Moon Nyeo Park1, Hyo Sook Song2, Myungsun Kim1, Min-Jung Lee1, Whisung Cho1, Hyun-Jin Lee1, Cho-Hyun Hwang1, Soojong Kim1, Yechae Hwang1, Beomku Kang1, Bonglee Kim1,2.
Abstract
Common care for glioblastoma multiforme (GBM) is a surgical resection followed by radiotherapy and temozolomide- (TMZ-) based chemotherapy. Unfortunately, these therapies remain inadequate involving severe mortality and recurrence. Recently, new approaches discovering combinations of multiple inhibitors have been proposed along with the identification of key driver mutations that are specific to each patient. To date, this approach is still limited by the lack of effective therapy. Hopefully, novel compounds derived from natural products are suggested as potential solutions. Inhibitory effects of natural products on angiogenesis and metastasis and cancer suppressive effect of altering miRNA expression are provident discoveries. Angelica sinensis accelerates apoptosis by their key substances influencing factors of apoptosis pathways. Brazilin displays antitumor features by making influence on reactive oxygen species (ROS) intensity. Sargassum serratifolium, flavonoids, and so on have antimetastasis effect. Ficus carica controls miRNA that inhibits translation of certain secretory pathway proteins during the UPR. Serratia marcescens and patupilone (EPO 906) are physically assessed materials through clinical trials related to GBM progression. Consequently, our review puts emphasis on the potential of natural products in GBM treatment by regulating multiple malignant cancer-related pathway solving pending problem such as reducing toxicity and side effect.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29181405 PMCID: PMC5664208 DOI: 10.1155/2017/8139848
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Apoptotic effect of natural products.
| Family names | Medical plants | Compounds/extracts | Dose/duration | Target molecules and additional efficacy | Cell lines | References |
|---|---|---|---|---|---|---|
| Hypericaceae |
| Hyperforin (HP), polyphenolic procyanidin B2 (PB-2), hypericin (HY) | HP 20 | Annexin V positive cells | LN229 | [ |
|
| ||||||
| Apiaceae |
| n-Butylidenephthalide (BP) | 75 | DBTRG-05MG, DBTRG 8401 (human) | DBTRG-05MG, GBM 8401 (human), RG2 (rat) | [ |
|
| ||||||
| Ericaceae |
| Flavonoid-rich fraction 6 (Fr6), proanthocyanidins (PAC) fraction | Fr6 concentration: 0, 50, 100, 150, 200, 250, 300 mg/L for 24 and 48 h (cell cycle distribution analysis) (Annexin V, PI) | ↑G1 phase | U87MG | [ |
|
| ||||||
| Menispermaceae |
| Ethanol extract | 250 | ↑GFAP, NCAM, | C6, U87 MG | [ |
|
| ||||||
| Ranunculaceae |
| Thymoquinone | 20 | ↑p62, cathepsin B | T98G, U87 MG | [ |
|
| ||||||
| Niclosamide | 1.5 | ↓WNT/CTNNB1-, NOTCH-, mTOR-, NF-kB | LN229, T98G, U87MG, U138, and U373 MG | [ | ||
|
| ||||||
| Fabaceae |
| Brazilin | 10 | ↑PARP | U87 MG | [ |
|
| ||||||
| Cannabaceae | Marijuana (cannabis) | Δ(9)-Tetrahydrocannabinol (THC) and cannabidiol (CBD) | 75 mg MPs (biodegradable polymeric microparticles) every 5 days | ↓KI67, CD31 | U87 MG | [ |
|
| ||||||
| Hopeaphenol, r2-viniferin | 20 | ↓caspase-9, caspase-3/7 | D-GBM | [ | ||
|
| ||||||
| Lamiaceae |
| Wogonin | 0–100 | ↑ AMPK, p53 | U87 MG, U343 MG, U373 MG, T98G, MCF-10A | [ |
|
| ||||||
| Rosaceae |
| Chokeberry extract, curcumin | 10 | ↓MMP-2, -14, -16, -17 | U373 MG | [ |
|
| ||||||
| (1) Fabaceae |
| ZSP (Zeng Sheng Ping) | 0, 50, 100 mg/kg/day | ↓notch 2, Hes1, CD133 | U87 MG, HSR-GBM1 JHH-GBM10, JHH-GBM14 | [ |
|
| ||||||
| Acanthaceae |
| Andrographolide | 10 | ↓PI3K/AKT, caspase-3 | U251, U87 MG | [ |
|
| ||||||
|
| 3-Deoxyschweinfurthin B (3dSB), 3-deoxyschweinfurthin B-like | 3dSB (500 nM), 3dSB-PNBS (500 nM), DMP-PNBS (1 M), or Y-27632 (10 M) for 48 h | ↑PARP, GRP78, PDI | SF-295 | [ | |
|
| ||||||
| Asteraceae |
| Jaceosidin | 100 | ↑p53, Bax, cytochrome c, caspase-3 | U87 MG | [ |
|
| ||||||
| Resveratrol | 30 | ↑ Atg5, beclin-1, LC3-II, PI3k class III | U-87 MG, U-251, U-138 MG | [ | ||
|
| ||||||
| Asteraceae |
| Tagitinin C | 10 | ↑PARP, p-p38, ULK1, LC3-II | U373 MG | [ |
|
| ||||||
| Apiaceae |
| (Z)-N-(2-(Dimethylamino)ethyl)-2-(3-((3-oxoisobenzofuran-1(3H)-ylidene)methyl)phenoxy)acetamide (PCH4) | 50 | ↓Nur77, JNK | DBTRG-05MG, GBM 8401 | [ |
|
| ||||||
| Clusiaceae |
|
| 80 | ↑NK cell, ROS | U87 MG, GBM 8401 | [ |
|
| ||||||
| High-fiber foods (such as corns, cereals, legumes, nuts, oil seed, soybean) | Inositol hexaphosphate (IP6) | 0.5, 1 mM for 24 h | ↑Bax, Bax: Bcl-2 ratio, cytosolic level of cytochrome c, Smac/Diablo (in the cytosol), 80 kD calpain, caspase-9, 85 kD PARP fragment | T98G | [ | |
|
| ||||||
| Anacardiaceae |
| Methyl gallate | 1 to 30 | ERK1/2 activation, apoptosis | U87MG | [ |
|
| ||||||
| Rutaceae |
|
| 1 mg/ml for 24, 48, 72 hours | ERK1/2, AKT activation, apoptosis in A1 mes-c-myc cells | U87MG, C6, U138 | [ |
|
| ||||||
| Lamiaceae |
| Oridonin | 5 | ↓RNA transferation, RanGTP | U87MG | [ |
|
| ||||||
| Berberidaceae |
| Deoxypodophyllotoxin (DPT) | 30 nM for 72 h | ↓Cdc2, cyclin B1, Cdc25c | U87MG, SF126 | [ |
|
| ||||||
| Primulaceae |
| Ardipusilloside I (ADS-I) | (20 | ↓vascular endothelial growth factor, C-reactive protein, tumor necrosis factor- | rat C6 glioma cells (in vivo) | [ |
|
| ||||||
| Curcuma |
| Supercritical CO2 extract of mango ginger (CA) | 0–100 mg/mL for 48 h | ↓STAT3, Bcl-2, mutant p53 expression | U87MG | [ |
|
| ||||||
| Curcumin, temozolomide | 7.5 | ↓phosphorylation of cyclin B1, cyclin D1 | C6, U251MG | [ | ||
|
| ||||||
| Rubiaceae |
| HDW extract | 0, 4, 8 mg/ml for 24 h | ↓Bcl-2/Bax ratio, AKT suppression ↑caspase-3, Bcl-2, Bax and ERK | U87MG | [ |
|
| ||||||
| Berberidaceae |
| Icariin | 0, 5, 10, 20 | ↓NF-kB, piwil4, Rac1 | U87MG | [ |
|
| ||||||
| Hispidulin | 10 | ↓Bcl2 | Human GBM | [ | ||
|
| ||||||
| Oleaceae |
| Olea europaea leaf extract (OLE) | 1 mg/ml, 2 mg/ml for 24 h | ↑ miR-153, miR-145, miR-137 | T98G, | [ |
|
| ||||||
| Moraceae |
| FCL extract | 0.125 mg/ml for 24 and 48 h | ↓HMGA2, VEGFA ↑HMGA2, VEGFA | T98G, | [ |
|
| ||||||
| Magnoliaceae |
| Honokiol | 10, 20 | ↓STAT3 signaling, ERK1/2, | U87MG, U251, | [ |
|
| ||||||
| Apocynaceae/Zingiberaceae |
| Crude alkaloid (CAERS), flavonoid (CFEZO) | 10 | ↓nuclear NF-kB, p65, survivin, XIAP, cyclin-D1, | U251 | [ |
|
| ||||||
| Primulaceae |
| Ardipusilloside I | 20 | ↑Beclin 1, LC3 | U373, T98G | [ |
|
| ||||||
| Berberidaceae |
| Berbamine derivative, BBMD3 | 1 | ↑miRNA-4284, JNK/AP-1 signaling, caspase-3 and cleavage of poly (ADP-ribose) polymerase (PARP) microRNA-4284 (miR-4284), phosphorylation of the cJun N-terminal kinase (JNK)/stress-activated protein kinase (SAPK) | Cancer stem-like cells (CSCs) from four GBM patients (PBT003, PBT008, PBT022, and PBT030) | [ |
|
| ||||||
| Solanaceae | Withaferin A (WA) | 0.025–3 | ↓G2/M cell cycle arrest, phosphorylation of AKT, mTOR, p70 S6K, c-Met, EGFR, Her2 | U87MG, U251, T98G | [ | |
|
| ||||||
|
|
| Lycorine | ↓actin, CYP3A4 cytostatic effect | B16F10 melanoma (mice) | [ | |
|
| ||||||
| Lavandin, peppermint, spearmint, sage, cherries, cranberries, | Perillyl alcohol (monoterpene alcohol) // | Perillyl alcohol: ↑TGF- | [ | |||
|
| ||||||
| Apiaceae | Angelica sinensis | Methanol extract of | 100 | ↑p16 and p53, CDK inhibitors | DBTRG-05MG, BALB/3T3 | [ |
|
| ||||||
| 4,6-Dichloro-5-aminopyrimidine | Thiazolo[5,4-d] pyrimidines | 48 h | T98G | [ | ||
|
| ||||||
| Apiaceae |
| Isochaihulactone | No concentration (all cell ER stress Western) | ↑DDIT3, NAG-1, PARP, caspase-3/9/7 | GBM cell lines | [ |
|
| ||||||
| Solanaceae |
| Kukoamine A | 0, 5, 10, 20 | ↑Bax, caspase-3, E-cadherin | Human GBM cells U251 & WJ1, | [ |
|
| ||||||
| Valerianaceae |
| N/A | 0, 20, 40, 60, 80 | ↓caspase-3/9, PARP | U87M (every experiment), U373MG | [ |
|
| ||||||
| N/A |
| Myricetin | 200 | ↑Bax, cleaved caspase-3, caspase-9, Bad | DBTRG-05MG, U251, U87MG | [ |
|
| ||||||
| Lamiaceae |
| Rosmarinic acid (RA) // luteolin-7-glucoside, caffeic acid, rosmarinic acid, protocatechuic acid, caftaric acid, ferulic acid, cichoric acid, Dulbecco's modified Eagle's medium (DMEM), Ampliflu Red, 2′,7′-Dichlorofluorescin diacetate (DCFH2-DA), 3-(4,5-dimethylthiazol2-yl)-2,5-diphenyl-tetrazolium bromide (MTT), HPLC grade acetonitrile, trifluoroacetic acid (TFA) | 0, 50, 100, 140, 170, 200, 250, 300, 400 | ↑intracellular reactive species (RS) (high density) | C6 rat glioblastoma | [ |
|
| ||||||
| N/A |
|
| 0, 2, 4, 6, 8, 10 | ↑cleaved PARP-1 | (Patient-derived) glioblastoma-initiating cells (GIC), U87MG | [ |
|
| ||||||
| Araceae |
| N/A | 0, 50, 100 | ↑Bax, cleaved caspase-3/8/9, mTOR (A172 only), LC3II/I, atg5, beclin-1, p-AMPK (both) | A172, U87MG, U251, U118, | [ |
|
| ||||||
| Araliaceae |
| Ginsenoside Rg3 | 10, 20, 40, 80, 120, 180 | ↓VEGF | Primary human umbilical vein endothelial cells (HUVECs), rat C6 glioma cell | [ |
|
| ||||||
| Lamiaceae |
| Thymol, carvacrol | 0, 25, 50, 100, 150, 200 | ZM treatment strengthen IR antiproliferation | A172 | [ |
|
| ||||||
| Boraginaceae |
| Shikonin | 2.5, 5, 7.5 | ↑p- | U87MG, U251 | [ |
|
| ||||||
| Zingiberaceae |
| Curcumin (diferuloylmethane) | 20, 50, 100 | ↑N/A | U87MG | [ |
|
| ||||||
| Taiwanese propolis (Erhmei (in central Taiwan), Fangliao (in southern Taiwan)) | Prenylflavanone (propolin G), Taiwanese propolis (TP) | 0, 2.5, 5, 10 | ↑sub-G1 cell population, caspase-3, caspase-8, caspase-9, cleavage form of PARP (85 kDa), p21waf1, ↓ procaspase-3, procaspase-8, procaspase-9, Bid, cyclin B1, cyclin D1, EC50 (20.5 | rat C6 glioma, DBTRG-05MG (human) | [ | |
|
| ||||||
| Curcumin | 20 | ↑G1 phase, p21, Egr-1, phosphorylated ERK1/2, JNK1/2, p38, phosphorylated Elk-1, ↓S phase, G2-M phase, cyclin D1/cell cycle arrest (G1 phase), ERK and JNK MAPK/Elk-1/Egr-1 signal cascade (p53-independent transcriptional activation of p21Waf1/Cip1) | U-87MG | [ | ||
|
| ||||||
| Ranunculaceae |
| Berberine | 50, 75, 100, 150 | ↑G1 phase, p27, Bax, caspase-9, caspase-3, PARP, ↓G2/M phase, S phase, CDK2, CDK4, cyclin D, cyclin E, Bcl-2 family, procaspase-9/cell cycle arrest (G1 phase), apoptosis (disruption of the mitochondrial membrane potential, activation of caspase pathways) | T98G | [ |
|
| ||||||
|
| Three benzopyrans (6-isobutyryl-5,7-dimethoxy-2,2-dimethyl-benzopyran (1), 7-hydroxy-6-isobutyryl-5-methoxy-2,2-dimethyl benzopyran (2), 5-hydroxy-6-isobutyryl-7-methoxy-2,2-dimethyl-benzopyran (3)) | 10 | ↑% sub-G1/cell cycle arrest (G2/M phase) | U-373MG | [ | |
ROS generation of natural products.
| Family names | Medical plants | Compounds/extracts | Dose/duration | Target molecules and additional efficacy | Cell lines | References |
|---|---|---|---|---|---|---|
| Zygophyllaceae |
| Balanitin-6 (28%), balanitin-7 (72%) | 830 nM for 24, 48, 72 h | ↓ATP (disorganization of actin cytoskeleton) | U373 | [ |
|
| ||||||
| Obtusaquinone | (In vitro) | ↑ROS, p53, caspase 3/7 | Gli36, U87 MG, U251, GBM8, GBM11/5, VU147 | [ | ||
|
| ||||||
| Clusiaceae |
|
| 80 | ↑NK cell, ROS | U87 MG, GBM 8401 | [ |
|
| ||||||
| N/A | Brazilian propolis (Pro) (not specific plant) | [Homocysteine (Hcy)] to provoke cognitive dysfunction | 100 | ↑relative fluorescence intensity | Neuroblastoma SH-SY5Y, glioblastoma U-251MG | [ |
Antiangiogenesis effect of natural products.
| Family names | Medical plants | Compounds/extracts | Dose/duration | Target molecules and additional efficacy | Cell lines | References |
|---|---|---|---|---|---|---|
| Araliaceae |
| Ginsenoside Rg3 | 0–180 | ↓VEGF, Bcl-2 (HUVEC mRNA), VEGFA, MVD | Rat C6 glioma cells | [ |
|
| ||||||
| Zingiberaceae |
| Supercritical CO2 extract | 0–100 | ↓VEGF mRNA, VEGF | U87MG | [ |
|
| ||||||
| Vitaceae |
| Red grape skin polyphenolic extract | 0–25 | ↓tube network formation, VEGF, S1P, ERK, p38/MAPK phosphorylation, S1P-induced PAF synthesis | U87MG | [ |
|
| ||||||
| Cannabaceae |
| Δ9-Tetrahydrocannabinol, cannabidiol | 7.5 mg/kg/day | ↓tumor vascularization (CD31 immunostaining) | U87MG | [ |
Figure 1Antiangiogenesis effect of natural products.
Antimetastasis effect of natural products.
| Family names | Medical plants | Compounds/extracts | Dose/duration | Target molecules and additional efficacy | Cell lines | References |
|---|---|---|---|---|---|---|
| Theaceae |
| Vitamin C (as ascorbic acid and as Mg, Ca, and palmitate ascorbate) 700 mg; L-lysine 1000 mg; L-proline 750 mg; L-arginine 500 mg; N-acetyl cysteine 200 mg; standardized green tea extract (80% polyphenol) 1000 mg; selenium 30 | 0–1000 | ↑TIMP-2 | LN-18, T-98G, A-172 | [ |
|
| ||||||
| Theaceae |
| Epigallocatechin gallate (EGCG) | 50–500 | ↓-2, MMP-9 | T-98G | [ |
|
| ||||||
| Sargassaceae |
| Hexane, ethanol, ethyl extract | 5–15 | ↓ MMP-2, MMP-9, C-Raf, MEK, ERK, phospho-ERK, wound area, invasive cells | U87MG | [ |
|
| ||||||
| Apiaceae |
| Osthole | 20–80 | ↓MMP-2, MMP–9 | GBM8401 | [ |
|
| ||||||
|
| Resveratrol | 5–20 | ↓MMP-2, NF- | Glioblastoma-initiating cells (GICs) | [ | |
|
| ||||||
| Flavonoids (plants, herbs, fruits) | Quercetin (QE), baicalein (BE), myricetin (ME) | 0–50 | ↓ ERK-activated COX-2/PGE2, MMP-9 | U87MG | [ | |
Figure 2Antimetastasis effect of natural products.
miRNA regulation of natural products.
| Family names | Medical plants | Compounds/extracts | Dose/duration | Target molecules and additional efficacy | Cell lines | References |
|---|---|---|---|---|---|---|
| Oleaceae |
| Oleuropein | 1 mg/ml, 2 mg/ml for 24 h | ↑miR-153, miR-145, miR-137 | T98G, | [ |
|
| ||||||
| Moraceae |
| Protocatechuic acid | 0.25 mg/ml for 24 h | ↑let-7d, VEGF | T98G, | [ |
|
| ||||||
| Boraginaceae |
| Shikonin | 2 mg/kg for 24 h | ↑miR-143, BAG3 | GSC | [ |
|
| ||||||
| Berberidaceae |
| Berbamine | 5 mM for 24 h | ↑caspase-3, PARP, miR-4284, JNK1, JNK 2, SAPK, phosphorylated c- Jun, total c-Fos | PBT003, PBT008, PBT022, | [ |
|
| ||||||
| Oleaceae |
| Oleuropein | 1 mg/ml for 24 h, 48 h | miR-181b, miR-153, miR-145, miR-137, ↑let-7d | T98G | [ |
|
| ||||||
| Zingiberaceae |
| Curcumin (diferuloylmethane) | 20 | ↑miR-146a | U-87 MG | [ |
Multidrug resistance and natural products.
| Family names | Medical plants | Compounds/extracts | Dose/duration | Target molecules and additional efficacy | Cell lines | References |
|---|---|---|---|---|---|---|
| Solanaceae |
| Withaferin A | 2.5 | ↑ERK1/2, HSP32, HSP70 | U87, U251, T98G | [ |
|
| ||||||
| Zingiberaceae |
| Methanol extract | 40 | Collateral sensitivity (hypersensitivity) | U87MG.ΔEGFR | [ |
|
| ||||||
| Clusiaceae |
| 8-Hydroxycudra-xanthone G, cudraxanthone I | 22.49 | Collateral sensitivity (hypersensitivity) | U87MG | [ |
|
| ||||||
| Moraceae |
| Isobavachalcone | 23.78 | Collateral sensitivity (hypersensitivity) | U87MG | [ |
Clinical trial of natural products.
| Phase | Title | Current state | Family names | Medical plants | Compounds/extracts | Additional therapy | Evaluation | Survival | Patients | References |
|---|---|---|---|---|---|---|---|---|---|---|
| Phase 1, | Patupilone (EPO 906) in patients with recurrent or progressive glioblastoma multiforme prior to and after secondary resection: an open-label phase I/II trial | Completed | Myxobacterium |
| Patupilone | Salvage treatment after patupilone consisted of bevacizumab, CCNU, a second RT round or surgery | Progression-free survival (PFS), overall survival (OS) at 6 months, patupilone concentration in tumor tissue/toxicity, patupilone concentration in plasma and translational analyses for predictive biomarkers, Aschen Aphasia Test, Rey Auditory-Verbal Learning Test, Rey Visual Design Learning Test, Rey-Osterrieth Complex analyses for predictive biomarkers | Median 85 weeks/median PFS 6 weeks | 9 patients/age 42–68 yrs | [ |
|
| ||||||||||
| Phase 2 | Clinical trial of | Completed | Enterobacteriaceae |
| ImuVert | Radiation therapy | Physical examination, KPS, assessment of weight, CBC count with differential, coagulation profile, serum chemistries, CT, MRI, thallium SPECT, time to progression of tumor | Median survival 69 weeks/median time to progression 11 weeks | 11 patients/newly diagnosed glioblastoma multiforme (GBM)/age 42–69 yrs | [ |